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Short-Term Outcomes in Newly Diagnosed Atrial Fibrillation and
Chronic Kidney Disease: How Important Is Ethnicity?
Wern Yew Ding, MRCP;* Ahsan A. Khan, MRCP;* Dhiraj Gupta, MD; Gregory Y. H. Lip, MD
A trial fibrillation (AF) often co-exists with other comor-bidities and has an increased prevalence and incidence
with worsening renal function.1–3 Overall management of the
condition includes detailed risk assessment, cardiovascular
risk reduction, and stroke prevention. The latter requires
appropriate use of oral anticoagulation (OAC) whether as
vitamin K antagonists (eg, warfarin) or non–vitamin K
antagonist oral anticoagulants (NOACs), and regional differ-
ences are evident in their uptake.4 Nevertheless, optimal OAC
use poses challenges if chronic kidney disease (CKD) is also
present, given the difficulties of maintaining good anticoag-
ulation control with warfarin5 (leading to prognostic implica-
tions6) and since all NOACs have a degree of renal
dependency for their excretion.7
The risk of stroke in AF is not homogeneous (being
dependent on various stroke risk factors that have been used
to formulate risk stratification schemes8), and presence of
CKD increases stroke risk, although not additive to stroke risk
stratification using the CH2ADS2-VASc score
9 given that many
of the pre-existing components of this score are already
strongly associated with renal function.
In the current issue of the Journal of the American Heart
Association (JAHA), Goto et al10 report on the impact of CKD
on 1-year outcomes in patients with newly diagnosed AF. Data
on 33 024 patients from the international, prospective
GARFIELD-AF (Global Anticoagulant Registry in the FIELD-
Atrial Fibrillation) were analyzed. They found that mild and
moderate-to-severe CKD were independently associated with
increased adjusted all-cause mortality at 1-year, adjusted
hazard ratio of 1.45 (95% CI 1.26–1.66) and 1.82 (95% CI
1.59–2.09), respectively. After adjusting for baseline charac-
teristics and antithrombotic use, moderate-to-severe CKD was
independently associated with increased 1-year risk of
stroke/systemic embolism, major bleeding, all-cause mortal-
ity, cardiovascular/noncardiovascular mortality, new-onset
acute coronary syndrome, and heart failure.
Perhaps the most interesting finding in the study is the
different impact of CKD among patients from Asia compared
with the rest of the world (RoW) (Figure). Patients from Asia
with newly diagnosed AF and no CKD have a lower 1-year
all-cause mortality of 2.2% (95% CI 2.05–2.77) compared
with the RoW of 3.4% (95% CI 3.31–3.91). At first glance, it
would appear that mild CKD does not contribute to any
increase in all-cause mortality among patients from Asia as
it does for the RoW. However, moderate-to-severe CKD
causes a dramatic rise in all-cause mortality among patients
from Asia such that their increased mortality (adjusted
hazard ratio of 2.44, 95% CI 1.83–3.26) significantly exceeds
that for RoW (adjusted hazard ratio of 1.64, 95% CI 1.41–
1.90).
Before attempting to rationalize this, a few points deserve
stating. First, patients from Asia had a lower body mass index,
prevalence of coronary artery disease, hypertension, and
hypercholesterolemia. While hazard ratios were adjusted for
various factors including hypertension, none of the other
formerly mentioned factors were taken into account.
Secondly, as acknowledged by the authors, the severity of
CKD was classified by individual investigators and no
laboratory data on renal function were collected. This has a
potential for major bias. More importantly, the methods used
to determine estimated glomerular filtration rate were not
standardized. It has previously been shown that the discrim-
inant capability for the 1-year risk of death in AF differed with
various estimated glomerular filtration calculation algorithms
(Table): The best was the Cockroft-Gault equation adjusted for
body surface area, followed by Cockroft-Gault, Chronic Kidney
Disease Epidemiology Collaboration, and Modification of Diet
in Renal Disease equations.11–14 Additionally, several studies
have demonstrated ethnic variations in normal reference
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values for glomerular filtration rate,15–17 which may be
improved with the inclusion of an ethnic coefficient.11
A previous study reported lower mortality rates in Asian
patients with CKD compared with whites.18 Therefore, in
context of the results reported by Goto et al,10 it may be
postulated that the presence of newly diagnosed AF in an
Asian population with advanced CKD alters the risk profile
significantly such that these patients experience a dramatic
rise in 1-year all-cause mortality, and any protective effects
that are conferred by ethnicity, environmental factors, or
lifestyle are lost. Alternatively, this may reflect ineffective
overall management of patients with moderate-to-severe CKD
in Asia.18
The study found that in Asia compared with the RoW, there
was less frequent use of vitamin K antagonistantiplatelet
therapy, but increased use of both antiplatelet monotherapy
CKD CKD
Asia ROW
AF
Higher mortality in moderate-to-
severe CKD
Poorer outcomes in moderate-to-
severe CKD 
Moderate-to-severe CKD is 
independently associated with 
increased mortality
Stepwise increase in mortality from 
no CKD to moderate-to-severe CKD
Mild and moderate-to-severe CKD is 
independently associated with 
increased mortality
AF
Poorer outcomes in moderate-to-
severe CKD 
Figure. The role of chronic kidney disease in patients with atrial fibrillation from Asia vs rest of the world
(ROW)—results from GARFIELD-AF registry. AF indicates atrial fibrillation; CKD, chronic kidney disease.
Table. Formulae to Calculate Estimated Glomerular Filtration Rate
Name Equation
Cockroft-Gault12 (140age)9(weight, kg)9(0.85 if female)/(729Cr)
IBW, kg (male)=50+[2.39(height, inches60)]
IBW, kg (female)=45.5+[2.39(height, inches60)]
Chronic Kidney Disease
Epidemiology Collaboration13
A9(SCr/B)C90.993 age9(1.159 if black), where A, B, and C are the following:
Female Male
SCr ≤0.7 A=144 SCr ≤0.9 A=141
B=0.7 B=0.9
C=0.329 C=0.411
SCr ≥0.7 A=144 SCr ≥0.9 A=141
B=0.7 B=0.9
C=1.209 C=1.209
Modification of Diet
in Renal Disease14
1869Serum Cr1.1549age0.20391.212 (if patient is black)90.742 (if female)
Cr indicates creatinine; IBW, ideal body weight; SCr, serum creatinine.
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and no antithrombotic therapy, as well as comparable rates of
NOACsantiplatelets. In addition, patients in Asia treated
with vitamin K antagonists were less likely to achieve time in
therapeutic range≥65% for target international normalized
ratio of 2.0 to 3.0 (no/mild CKD: 19.8% in Asia versus 46.3%
in RoW and moderate-to-severe CKD: 16.0% in Asia versus
44.4% in RoW).
These data on poorer time in therapeutic range are
supportive of the increased efficacy and safety with NOACs in
Asians compared with non-Asians.19,20 Despite the disparity
in antithrombotic management, observed stroke/systemic
embolism and major bleeding rates were rather similar for
both regions and CKD groups. However, event rates were low
and hence true differences may not have been detected.
Several limitations are inherent when performing studies
such as this using registry data. An important limitation to
consider is that the CKD stage was assessed only at the time
of enrollment and therefore did not account for possible time-
dependent changes in renal function. Asian patients have
previously been reported to have faster progression of CKD.18
While taking into account time-dependent change in renal
function is less important when assessing short-term out-
comes, it is imperative that future studies with longer follow-
up include this to enable accurate assessment of the effects
of renal function on morbidity and mortality outcomes in
patients with AF.
In summary, the study by Goto et al10 has demonstrated a
negative impact of CKD in newly diagnosed AF patients, with
greater effect seen in moderate-to-severe CKD patients from
Asia. Future studies are needed to confirm the findings and
evaluate the ethnic differences reported here.
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